FDA Cautions Against Use of Reminyl for Mild Cognitive Impairment

Editor’s note: Ortho-McNeil Neurologics, Inc., announced on April 11, 2007, that its symbol name Reminyl (galantamine hydrobromide) would be changed to Razadyne in mode to FDA reports of prescribing and dispensing errors due to confusedness of the names Reminyl and the diabetes drug Amaryl (glimepiride), which is marketed by Sanofi-Aventis.
April 1, 2007
This is a part of article FDA Cautions Against Use of Reminyl for Mild Cognitive Impairment Taken from "Glimepiride Amaryl Tablets" Information Blog